Drug class first: The four approved pillars of PAH therapy are endothelin receptor antagonists, phosphodiesterase-5 inhibitors, prostacyclin analogues and the soluble guanylate cyclase stimulator riociguat. Scan the options for one of these classes.
Option elimination: Icatibant treats hereditary angioedema by blocking bradykinin, no link to lung vessels, so it goes. Labetalol is a routine antihypertensive beta/alpha blocker with no PAH indication, so it goes. Sodium nitroprusside is an emergency systemic vasodilator, not a chronic PAH drug, so it goes. That leaves bosentan.
Why bosentan fits: It antagonises endothelin receptors. Endothelin is up in PAH and drives pulmonary vasoconstriction and remodelling, so blocking it directly targets the disease, which is why it is a licensed therapy.
Exam pearl: Remember bosentan = endothelin blocker = liver monitoring needed, and it is teratogenic, so it is given with contraception in women of childbearing age.
Ref: Harrison's Principles of Internal Medicine, 20e.